Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4741728
Max Phase: Preclinical
Molecular Formula: C21H15ClFNO3
Molecular Weight: 383.81
Molecule Type: Unknown
Associated Items:
ID: ALA4741728
Max Phase: Preclinical
Molecular Formula: C21H15ClFNO3
Molecular Weight: 383.81
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(O)Cc1ccccc1NC(=O)c1cccc(-c2ccc(Cl)cc2)c1F
Standard InChI: InChI=1S/C21H15ClFNO3/c22-15-10-8-13(9-11-15)16-5-3-6-17(20(16)23)21(27)24-18-7-2-1-4-14(18)12-19(25)26/h1-11H,12H2,(H,24,27)(H,25,26)
Standard InChI Key: DUAGRVPHKSIHCC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 383.81 | Molecular Weight (Monoisotopic): 383.0724 | AlogP: 5.03 | #Rotatable Bonds: 5 |
Polar Surface Area: 66.40 | Molecular Species: ACID | HBA: 2 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.00 | CX Basic pKa: | CX LogP: 5.10 | CX LogD: 1.94 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.65 | Np Likeness Score: -1.18 |
1. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N. (2020) Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure., 63 (17): [PMID:32856916] [10.1021/acs.jmedchem.0c01020] |
Source(1):